FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 169.19

Change

-2.32 (-1.35)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.67 (-0.44%)

USD 41.04B
FHLC Fidelity® MSCI Health Care In..

-0.48 (-0.67%)

USD 2.94B
FXH First Trust Health Care AlphaD..

-1.47 (-1.35%)

USD 1.23B
XHE SPDR® S&P Health Care Equipme..

-1.46 (-1.67%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.33 (-1.34%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.86 (-2.28%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-1.15 (-1.22%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.29 (-1.00%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.14 (-1.82%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

N/A

USD 0.01B

ETFs Containing FBT

FBT:CA First Trust NYSE Arca Bio.. 99.96 % 0.00 %

N/A

CAD 1.83M
FHM:CA 99.89 % 0.78 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.04% 71% C- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.04% 71% C- 51% F
Trailing 12 Months  
Capital Gain 15.92% 57% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.92% 57% F 50% F
Trailing 5 Years  
Capital Gain 39.63% 67% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.63% 67% D+ 68% D+
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike